Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in Nat Med

Retrieve available abstracts of 47 articles:
HTML format



Single Articles


    May 2021
  1. LIU D, Lin JR, Robitschek EJ, Kasumova GG, et al
    Evolution of delayed resistance to immunotherapy in a melanoma responder.
    Nat Med. 2021 May 3. pii: 10.1038/s41591-021-01331.
    PubMed     Abstract available


    February 2021
  2. MENZIES AM, Amaria RN, Rozeman EA, Huang AC, et al
    Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-020-01188.
    PubMed     Abstract available


  3. ROZEMAN EA, Hoefsmit EP, Reijers ILM, Saw RPM, et al
    Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-020-01211.
    PubMed     Abstract available


    January 2021
  4. PEREZ-GUIJARRO E, Yang HH, Araya RE, El Meskini R, et al
    Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
    Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01252.
    PubMed    


  5. HU Z, Leet DE, Allesoe RL, Oliveira G, et al
    Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
    Nat Med. 2021 Jan 21. pii: 10.1038/s41591-020-01206.
    PubMed     Abstract available


  6. STOWER H
    Microbiome transplant-induced response to immunotherapy.
    Nat Med. 2021;27:21.
    PubMed    


  7. YU J, Green MD, Li S, Sun Y, et al
    Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
    Nat Med. 2021;27:152-164.
    PubMed     Abstract available


    October 2020
  8. CEREZO-WALLIS D, Contreras-Alcalde M, Troule K, Catena X, et al
    Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.
    Nat Med. 2020 Oct 19. pii: 10.1038/s41591-020-1073.
    PubMed     Abstract available


  9. DUMMER R, Lebbe C, Atkinson V, Mandala M, et al
    Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Nat Med. 2020;26:1557-1563.
    PubMed     Abstract available


  10. ALGAZI AP, Othus M, Daud AI, Lo RS, et al
    Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
    Nat Med. 2020;26:1564-1568.
    PubMed     Abstract available


  11. RYLL B
    From good to great: what patients can do for your medical research.
    Nat Med. 2020;26:1508.
    PubMed    


    July 2020
  12. ALLEN BM, Hiam KJ, Burnett CE, Venida A, et al
    Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.
    Nat Med. 2020;26:1125-1134.
    PubMed     Abstract available


    June 2020
  13. LIU D, Schilling B, Liu D, Sucker A, et al
    Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
    Nat Med. 2020 Jun 19. pii: 10.1038/s41591-020-0975.
    PubMed     Abstract available


  14. LIU Y, Jain A, Eng C, Way DH, et al
    A deep learning system for differential diagnosis of skin diseases.
    Nat Med. 2020;26:900-908.
    PubMed     Abstract available


    May 2020
  15. OSTENDORF BN, Bilanovic J, Adaku N, Tafreshian KN, et al
    Common germline variants of the human APOE gene modulate melanoma progression and survival.
    Nat Med. 2020 May 25. pii: 10.1038/s41591-020-0879.
    PubMed     Abstract available


    April 2020
  16. PEREZ-GUIJARRO E, Yang HH, Araya RE, El Meskini R, et al
    Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
    Nat Med. 2020 Apr 13. pii: 10.1038/s41591-020-0818.
    PubMed     Abstract available


    March 2020
  17. TADROS AR, Romanyuk A, Miller IC, Santiago A, et al
    STAR particles for enhanced topical drug and vaccine delivery.
    Nat Med. 2020;26:341-347.
    PubMed     Abstract available


    February 2020
  18. FAIRFAX BP, Taylor CA, Watson RA, Nassiri I, et al
    Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.
    Nat Med. 2020;26:193-199.
    PubMed     Abstract available


    December 2019
  19. AUSLANDER N, Lee JS, Ruppin E
    Reply to: 'IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma'.
    Nat Med. 2019;25:1836-1838.
    PubMed    


  20. CARTER JA, Gilbo P, Atwal GS
    IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2019;25:1833-1835.
    PubMed    


  21. LIU D, Schilling B, Liu D, Sucker A, et al
    Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
    Nat Med. 2019;25:1916-1927.
    PubMed     Abstract available


    July 2019
  22. RIBAS A, Lawrence D, Atkinson V, Agarwal S, et al
    Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Nat Med. 2019 Jul 2. pii: 10.1038/s41591-019-0535.
    PubMed     Abstract available


    June 2019
  23. RIBAS A, Lawrence D, Atkinson V, Agarwal S, et al
    Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0476.
    PubMed     Abstract available


  24. ASCIERTO PA, Ferrucci PF, Fisher R, Del Vecchio M, et al
    Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0448.
    PubMed     Abstract available


  25. ROZEMAN EA, Blank CU
    Combining checkpoint inhibition and targeted therapy in melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0482.
    PubMed    


  26. SULLIVAN RJ, Hamid O, Gonzalez R, Infante JR, et al
    Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0474.
    PubMed     Abstract available


    May 2019
  27. ZAPPASODI R, Sirard C, Li Y, Budhu S, et al
    Rational design of anti-GITR-based combination immunotherapy.
    Nat Med. 2019;25:759-766.
    PubMed     Abstract available


    March 2019
  28. NEWMAN S, Fan L, Pribnow A, Silkov A, et al
    Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.
    Nat Med. 2019 Mar 4. pii: 10.1038/s41591-019-0373.
    PubMed     Abstract available


  29. LONG GV
    Making a difference to many.
    Nat Med. 2019;25:356.
    PubMed    


  30. TURAJLIC S
    Standing on the shoulders of giants.
    Nat Med. 2019;25:357.
    PubMed    


    February 2019
  31. HUANG AC, Orlowski RJ, Xu X, Mick R, et al
    A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
    Nat Med. 2019 Feb 25. pii: 10.1038/s41591-019-0357.
    PubMed     Abstract available


    December 2018
  32. TRUCCO LD, Mundra PA, Hogan K, Garcia-Martinez P, et al
    Publisher Correction: Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
    Nat Med. 2018 Dec 18. pii: 10.1038/s41591-018-0325.
    PubMed     Abstract available


  33. TRUCCO LD, Mundra PA, Hogan K, Garcia-Martinez P, et al
    Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
    Nat Med. 2018 Dec 3. pii: 10.1038/s41591-018-0265.
    PubMed     Abstract available


    November 2018
  34. ROBERT C
    Is earlier better for melanoma checkpoint blockade?
    Nat Med. 2018;24:1645-1648.
    PubMed     Abstract available


    October 2018
  35. CEREZO M, Guemiri R, Druillennec S, Girault I, et al
    Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
    Nat Med. 2018 Oct 29. pii: 10.1038/s41591-018-0217.
    PubMed     Abstract available


  36. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0252.
    PubMed     Abstract available


  37. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0251.
    PubMed     Abstract available


  38. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
    Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2018 Oct 17. pii: 10.1038/s41591-018-0247.
    PubMed     Abstract available


  39. BLANK CU, Rozeman EA, Fanchi LF, Sikorska K, et al
    Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0198.
    PubMed     Abstract available


  40. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0197.
    PubMed     Abstract available


    August 2018
  41. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
    Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2018 Aug 20. pii: 10.1038/s41591-018-0157.
    PubMed     Abstract available


    January 2018
  42. BOSHUIZEN J, Koopman LA, Krijgsman O, Shahrabi A, et al
    Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
    Nat Med. 2018 Jan 15. pii: nm.4472. doi: 10.1038/nm.4472.
    PubMed     Abstract available


    October 2017
  43. MURGAI M, Ju W, Eason M, Kline J, et al
    KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis.
    Nat Med. 2017;23:1176-1190.
    PubMed     Abstract available


    August 2017
  44. XUE Y, Martelotto L, Baslan T, Vides A, et al
    An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
    Nat Med. 2017;23:929-937.
    PubMed     Abstract available


    July 2017
  45. MAYORCA-GUILIANI AE, Madsen CD, Cox TR, Horton ER, et al
    ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix.
    Nat Med. 2017;23:890-898.
    PubMed     Abstract available


    December 2016
  46. PEINADO H, Alec kovic M, Lavotshkin S, Matei I, et al
    Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
    Nat Med. 2016;22:1502.
    PubMed    


    October 2016
  47. LINNEMANN C, van Buuren MM, Bies L, Verdegaal EM, et al
    Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
    Nat Med. 2016;22:1192.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: